The store will not work correctly when cookies are disabled.
5-(3-Ethylbenzo[d]isoxazol-6-yl)-3-(oxazol-2-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one
ID: ALA3715861
PubChem CID: 90109370
Max Phase: Preclinical
Molecular Formula: C18H13N5O3
Molecular Weight: 347.33
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: CCc1noc2cc(-c3cc(=O)n4ncc(-c5ncco5)c4[nH]3)ccc12
Standard InChI: InChI=1S/C18H13N5O3/c1-2-13-11-4-3-10(7-15(11)26-22-13)14-8-16(24)23-17(21-14)12(9-20-23)18-19-5-6-25-18/h3-9,21H,2H2,1H3
Standard InChI Key: XPLGHUMUWMJNMF-UHFFFAOYSA-N
Molfile:
RDKit 2D
26 30 0 0 0 0 0 0 0 0999 V2000
0.2917 0.7475 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0028 1.5132 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.3155 0.7475 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.3155 -0.7475 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0028 -1.5132 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.2917 -0.7475 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.7138 -1.2033 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.5889 0.0182 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7138 1.2033 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.9991 -2.7132 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.3751 3.8801 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
2.1749 2.6315 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6243 2.9682 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.7308 4.4644 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.3406 5.0280 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-7.6468 1.0526 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-8.5184 2.2403 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-7.6395 3.4592 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-6.2188 2.9991 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-6.2234 1.5040 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.9312 0.7344 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.6168 1.4950 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.6117 2.9912 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.9221 3.7609 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-8.1069 4.8826 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-9.2813 5.1293 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 1 0
1 6 1 0
7 8 2 0
8 9 1 0
6 7 1 0
1 9 2 0
5 10 2 0
11 12 1 0
12 13 2 0
13 14 1 0
14 15 2 0
11 15 1 0
9 12 1 0
16 17 1 0
17 18 2 0
18 19 1 0
19 20 1 0
16 20 1 0
21 22 1 0
22 23 2 0
23 24 1 0
19 24 2 0
20 21 2 0
25 26 1 0
18 25 1 0
3 22 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 347.33 | Molecular Weight (Monoisotopic): 347.1018 | AlogP: 3.05 | #Rotatable Bonds: 3 |
Polar Surface Area: 102.22 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 1 |
#RO5 Violations: ┄ | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 10.64 | CX Basic pKa: 0.33 | CX LogP: 1.59 | CX LogD: 1.59 |
Aromatic Rings: 5 | Heavy Atoms: 26 | QED Weighted: 0.54 | Np Likeness Score: -1.28 |
References
1. (2014) Heterocyclic compounds for the inhibition of pask, |
2. (2015) Heterocyclic compounds for the inhibition of pask, |